

01-91000-08

Original Effective Date: 01/15/10

Reviewed: 12/04/25

Revised: 12/15/25

Subject: Ingestible pH and Pressure Capsule

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Update			

DESCRIPTION:

An ingestible pH and pressure capsule (e.g., SmartPill GI Monitoring System) is proposed as a means of evaluating gastric emptying, small bowel, colonic and whole gut transit times. This technology is used to evaluate suspected gastrointestinal motility disorders such as gastroparesis, intestinal dysmotility and constipation.

The U.S. Food and Drug Administration (FDA) cleared the SmartPill GI Monitoring System for marketing via a 510(k) application. Indications for use states the SmartPill GI Monitoring System is indicated for use in evaluating patients with suspected delayed gastric emptying (gastroparesis) and for the evaluation of colonic transit in patients with chronic constipation and used to aid in differentiating slow and normal transit constipation.

Summary of Evidence: Thwaites et al (2024) provided an overview of the structure and potential impact of ingestible devices in development that are relevant to the gastrointestinal tract. Technical success of ingestible electronic devices relies on the ability to miniaturize the microelectronic circuits, sensors and components for interventional functions while being sufficiently powered to fulfil the intended function. These devices offer the advantages of being convenient and minimally invasive, with real-time assessment often possible and with minimal interference to normal physiology. Safety has not been a limitation, but defining and controlling device location in the gastrointestinal tract remains challenging. The success of capsule endoscopy has buoyed enthusiasm for the concepts, but few ingestible devices have reached clinical practice to date, partly due to the novelty of the information they provide and also due to the challenges of adding this novel technology to established clinical paradigms. With ongoing technological advancement and as understanding of their potential impact emerges, acceptance of such technology will grow. These devices have the capacity to provide unique insight into gastrointestinal physiology and pathophysiology. Interventional functions, such as sampling of tissue or luminal contents and delivery of therapies, may further enhance their ability to sharpen gastroenterological diagnoses,

monitoring and treatment. The authors noted that while still in relative infancy, the role of ingestible devices in gastroenterology is exciting and provides an opportunity to greatly expand our understanding of gastrointestinal physiology and indeed pathophysiology in a relatively undisturbed and minimally invasive way. It also provides a tool by which changes that may occur in response to pharmacological, dietary or other health interventions over time can be monitored. The authors concluded that the development of miniaturized ingestible microelectronic-based devices offers exciting prospects for enhancing gastroenterological research and the delivery of personalized, point-of-care medicine.

In a review authors Kalantar-Zadeh et al (2017) presented an overview of the gut structure and discusses current and emerging ingestible technologies. Ingestible sensing capsules are fast emerging as a critical technology that has the ability to greatly impact health, nutrition, and clinical areas. These ingestible devices are noninvasive and hence are very attractive for customers. With widespread access to smart phones connected to the Internet, the data produced by this technology can be readily seen and reviewed online and accessed by both users and physicians. The outputs provide invaluable information to reveal the state of gut health and disorders as well as the impact of food, medical supplements, and environmental changes on the gastrointestinal tract. One unique feature of such ingestible sensors is that their passage through the gut lumen gives them access to each individual organ of the gastrointestinal tract. Therefore, ingestible sensors offer the ability to gather images and monitor luminal fluid and the contents of each gut segment including electrolytes, enzymes, metabolites, hormones, and the microbial communities. As such, an incredible wealth of knowledge regarding the functionality and state of health of individuals through key gut biomarkers can be obtained. The authors noted that the field of ingestible sensors is still in its absolute infancy and their information about many different sections of the gastro-intestinal tract is still rudimentary. Their “acquisition of knowledge of the gut is so far limited to just a few ingestible sensors including pH, temperature, and pressure capsules as well as camera-based devices. Even such capsules have only been used in relatively low numbers, considering the potential population in need of them. The costs associated with the use and administration of ingestible devices are still high, they have reliability issues, governmental regulatory barriers are still problematic, and lack of familiarity of medical doctors and food scientists with the output information from capsule signals is also a significant issue.”

In a review Lacy et al (2022) outlines a strategy for defining, diagnosing, and managing medically refractory gastroparesis. The review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee and the AGA Governing Board. The best practice statement includes the following for gastric emptying: “Clinicians should verify appropriate methodology of the gastric emptying study to ensure an accurate diagnosis of delayed gastric emptying.” “Because the wireless motility capsule, an inanimate object, identifies the phase III activity front of the migrating motor complex rather than overall gastric emptying, a meal-based test provides better physiological assessment of gastric emptying and is thus recommended as the first-line test of gastric emptying over the wireless motility capsule.

POSITION STATEMENT:

Measurement of gastrointestinal transit times, including gastric emptying and colonic transit times, using an ingestible pH and pressure capsule (e.g., SmartPill Monitoring System) is considered **experimental or investigational** for all indications, including the evaluation of gastroparesis, constipation and gastrointestinal motility disorders. The evidence is insufficient to determine the effects

of the technology on health outcomes.

BILLING/CODING INFORMATION:

CPT Coding:

91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report (investigational)
-------	---

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at [Coverage Protocol Exemption Request](#).

DEFINITIONS:

Gastroparesis: delayed gastric emptying.

RELATED GUIDELINES:

[Esophageal pH Monitoring, 01-91000-01](#)

[Wireless Capsule Endoscopy, 01-91000-35](#)

OTHER:

Other names use to describe SmartPill GI Monitoring System:

Note: The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Gastrointestinal motility system

Gastrointestinal pH and pressure monitoring equipment

SmartPill

Wireless GI motility monitoring

Wireless motility capsule

REFERENCES:

1. Abell TL, Camilleri M, Donohoe K et al. Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine. *Journal of Nuclear Medicine Technology* 2008; 36(1):44-54.
2. Blue Cross Blue Shield Association Medical Policy Reference Manual-Ingestible pH and Pressure Capsule 2.01.81, Archived 01/21.
3. Camilleri M, Parkman HP, Shafi MA et al 2013. Clinical guideline: management of gastroparesis. *American Journal of Gastroenterology* 2013; 108(1): 18-37.
4. Camilleri M, Thorne NK, Ringel Y et al. Wireless pH-motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. *Neurogastroenterology & Motility* 2010; 22(8): 874-882.
5. Cassilly D, Kantor S, Knight LC, et al. Gastric emptying of a non-digestible solid: assessment with simultaneous SmartPill pH and pressure capsule, antroduodenal manometry, gastric emptying scintigraphy. *Neurogastroenterology and Motility* 2008 Apr; 20(4): 311-319.
6. Green AD, Belkind-Gerson J, Surjanhata BC, et al. Wireless motility capsule test in children with upper gastrointestinal symptoms. *J Pediatr*. 2013 Jun;162(6):1181-7. [Abstract]
7. Kalantar-Zadeh K, Ha N, Ou JZ, et al. Ingestible Sensors. *ACS Sens*. 2017 Apr 28;2(4):468-483.
8. Kuo B, Maneerattanaporn M, Lee AA et al. Generalized transit delay on wireless motility capsule testing in patients with clinical suspicion of gastroparesis, small intestinal dysmotility, or slow transit constipation. *Digestive Disease Science* 2011; 56(10): 2928-38.
9. Kuo B, McCallum RW, Koch KL et al. Comparison of gastric emptying of a nondigestible capsule to a radio-labeled meal in healthy and gastroparetic subjects. *Alimentary Pharmacology & Therapeutics* 2008; 27(2): 186-196.
10. Lacy BE, Tack J, Gyawali CP. AGA Clinical Practice Update on Management of Medically Refractory Gastroparesis: Expert Review. *Clin Gastroenterol Hepatol*. 2022 Mar;20(3):491-500.
11. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. *Digestive Diseases and Sciences* 2009; 54(10): 2167-2174.
12. Parkman HP, Hasler WL, Fisher RS et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. *Gastroenterology* 2004; 127(5): 1592-622.
13. Parkman HP. Assessment of gastric emptying and small-bowel motility: scintigraphy, breath tests, manometry, and SmartPill. *Gastrointestinal Endoscopy Clinics of North America* 2009; 19(1): 49-55.
14. Rao SS, Camilleri M, Hasler WL et al. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. *Neurogastroenterology and Motility* 2011; 23(1): 8-23.
15. Rao SS, Kuo B, McCallum RW et al. Investigation of colonic and whole gut transit with wireless motility capsule and radioopaque markers in constipation. *Clinical Gastroenterology Hepatology* 2009; 7(5):537-544.
16. Rao SS, Mysore K, Attaluri A et al. Diagnostic utility of wireless motility capsule in gastrointestinal dysmotility. *Journal of Clinical Gastroenterology* 2011; 45(8): 684-90. [Abstract]

17. Rauch S, Krueger K, Turan A, et al. Use of wireless motility capsule to determine gastric emptying and small intestinal transit times in critically ill trauma patients. *J Crit Care*. 2012 Oct;27(5): 534.e7-12.
18. Rodriguez L, Heinz N, Colliard K, et al. Diagnostic and clinical utility of the wireless motility capsule in children: A study in patients with functional gastrointestinal disorders. *Neurogastroenterol Motil*. 2021 Apr;33(4):e14032. [Abstract]
19. Saad RJ, Hasler WL. A technical review and clinical assessment of the wireless motility capsule. *Gastroenterol Hepatol (N Y)*. 2011 Dec;7(12):795-804.
20. Sangnes DA, Sjøfteland E, Bekkelund M, et al. Wireless motility capsule compared with scintigraphy in the assessment of diabetic gastroparesis. *Neurogastroenterol Motil*. 2020 Apr;32(4):e13771.
21. Sarosiek I, Selover KH, Katz LA et al. The assessment of regional gut transit times in health controls and patients with gastroparesis using wireless motility technology. *Alimentary Pharmacology and Therapeutics* 2010; 31(2):313-322.
22. Stein E, Berger Z, Hutfless S, et al. Wireless Motility Capsule Versus Other Diagnostic Technologies for Evaluating Gastroparesis and Constipation: A Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 May. Report No.: 13-EHC060-EF.
23. Thwaites PA, Yao CK, Halmos EP, et al. Review article: Current status and future directions of ingestible electronic devices in gastroenterology. *Aliment Pharmacol Ther*. 2024 Feb;59(4):459-474.
24. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. *Am J Gastroenterol*. 2000 Jun;95(6):1456-62. [Abstract]
25. Tran K, Brun R, Kuo B. Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice. *Therap Adv Gastroenterol*. 2012 Jul;5(4):249-60.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 12/04/25.

GUIDELINE UPDATE INFORMATION:

01/15/10	New Medical Coverage Guideline.
12/15/10	Annual review. Maintain position statement. Updated references.
01/01/11	Annual HCPCS coding update; added 0242T.
02/15/12	Annual review. Maintain position statement (experimental or investigational); revised to include constipation and other gastrointestinal motility disorders and added statement "the impact of measuring gastric emptying using an ingestible pH and pressure capsule on health outcome is unknown." Updated description and references.
01/01/13	Annual HCPCS coding update; deleted 0242T and added 91112.
03/15/13	Annual review; no change in position statement. Updated references.
06/15/14	Annual review; no change in position statement. Added Medicare Advantage products program exception Updated references.

05/15/17	Review; no change in position statement. Updated references.
12/15/19	Review; no change in position statement. Updated references.
12/15/21	Review; no change in position statement. Updated references.
05/22/23	Update to Program Exceptions section.
12/15/23	Review; revised position statement. Updated references.
12/15/24	Review; no change in position statement. Updated references.
12/15/25	Review; no change in position statement.